Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Net Income: 2022-2025

Historic Net Income for Entrada Therapeutics (TRDA) over the last 4 years, with Sep 2025 value amounting to -$44.2 million.

  • Entrada Therapeutics' Net Income fell 215.75% to -$44.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$103.5 million, marking a year-over-year decrease of 288.29%. This contributed to the annual value of $65.6 million for FY2024, which is 1087.80% up from last year.
  • According to the latest figures from Q3 2025, Entrada Therapeutics' Net Income is -$44.2 million, which was down 2.45% from -$43.1 million recorded in Q2 2025.
  • Entrada Therapeutics' 5-year Net Income high stood at $55.0 million for Q2 2024, and its period low was -$44.2 million during Q3 2025.
  • In the last 3 years, Entrada Therapeutics' Net Income had a median value of -$9.5 million in 2023 and averaged -$4.2 million.
  • Its Net Income has fluctuated over the past 5 years, first spiked by 449.49% in 2024, then crashed by 215.75% in 2025.
  • Entrada Therapeutics' Net Income (Quarterly) stood at -$24.6 million in 2022, then skyrocketed by 61.43% to -$9.5 million in 2023, then skyrocketed by 111.63% to $1.1 million in 2024, then crashed by 215.75% to -$44.2 million in 2025.
  • Its Net Income was -$44.2 million in Q3 2025, compared to -$43.1 million in Q2 2025 and -$17.3 million in Q1 2025.